AI Article Synopsis

  • Over 50% of colorectal cancer patients develop liver metastases, with surgical resection offering the best chance of long-term survival, especially for those without widespread disease.
  • Current strategies focus on improving surgical outcomes via better patient selection and the use of neoadjuvant chemotherapy to enhance resectability and lower recurrence rates.
  • Multidisciplinary care is crucial for effective treatment planning and management of patients with colorectal liver metastases to optimize their chances for successful outcomes.

Article Abstract

Background: Over 50% of patients with colorectal cancer will develop liver metastases. Only a minority of patients present with technically resectable disease. Around 40% of those undergoing surgical resection are alive five years after their diagnosis compared with less than 1% for those with disseminated disease treated with systemic chemotherapy. Surgical resection remains the only possibility for long-term survival for these patients and great efforts have been made to increase the rates of resection whilst improving long-term outcomes.

Summary: This review considers current technical and oncological criteria for resection, as well as targeted approaches to stratify underlying tumor biology in order to better predict long-term benefit. The role of neoadjuvant and perioperative systemic chemotherapy is critically reviewed, with suggestions for patient stratification in order to identify those who are likely to derive the greatest benefit. The key role of multidisciplinary assessment and decision making for these complex patients is also discussed.

Key Messages: Surgery remains the optimal treatment for colorectal liver metastases (CRLM). Despite the curative intent of surgical resection, the majority of patients develop recurrence. Surgical strategies should therefore be adopted to maximize the potential for repeat resections in the event of recurrence. Although a number of preoperative prognostic markers have been identified, none are absolute contraindications to resection. In order to reduce postoperative recurrence, neo-adjuvant chemotherapy is now the standard of care in a number of countries. The evidence base for this approach is contentious, and the potential benefit of such a strategy is likely to be greatest in patients with high oncological risk disease. Multidisciplinary care is essential to ensure the optimal management of these complex patients. In addition, all patients with CRLM should be discussed with specialist hepatobiliary surgeons.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159727PMC
http://dx.doi.org/10.1159/000449348DOI Listing

Publication Analysis

Top Keywords

liver metastases
12
surgical resection
12
colorectal liver
8
patients
8
systemic chemotherapy
8
complex patients
8
resection
6
metastases critical
4
critical review
4
review state
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!